English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

This opinion letter focuses on fighting meningitis in the African meningitis belt. Another meningitis season has ended in the region stretching from Senegal to Ethiopia [1]. The 2016-2017 meningitis season had left behind 28,000 suspected cases and 2,500 deaths. Bacterial meningitis is mainly due to 3 types of bacteria that are independently targeted by specific vaccines [2]. Since the introduction of the low-cost monovalent conjugate MenAfriVac® vaccine starting in December 2010 to everyone aged 1-29 in 27 countries, over 277 million people were immunized against serogroupA meningococcal meningitis (NmA). Despite the major success in controlling the NmA in that specific region, meningitis at large still circulates and other variants of the disease cause local outbreaks [3]. Streptococcus pneumoniae (Sp) causes recurrent epidemics in the region [2] and Neisseria meningitidis (Nm) serogroups C, W and X currently cause the majority of cases [4,5].

Fighting Meningitis in Africa: A Call for a Multi Sectorial Action